Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Gene regulatory network transitions reveal the central transcription factors in lung adenocarcinoma progression.

  PMID 41559111 · PMC12873405 · NPJ systems biology and applications · 2026 · 7 claims · 8 setups

  Full-text index only

  NR2F1 is a central transcription factor in LUAD progression, identified independently through GRN architecture transitions and gene regulation dynamics analysis

  luad epithelial myeloid nr2f1 single-cell gene binding

• The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.

  PMID 42011021 · PMC13096693 · Clinical and translational medicine · 2026 · 6 claims · 8 setups

  Full-text index only

  KRAS-mutant LUAD patients show significantly poorer pathological response and inferior long-term survival after neoadjuvant immunotherapy compared to KRAS-wildtype patients

  resected resectable epithelial cd4t_treg_tnfrsf4 scrna-seq retrospective cnv

• Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancer.

  PMID 41966692 · PMC13130634 · Cell reports. Medicine · 2026 · 8 claims · 6 setups

  Full-text index only

  Different histologic components within cSCLC tumors share a monoclonal origin

  ffpe sections tumor luad multi-region spatial single-nucleus

• Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

  PMID 41956098 · PMC7619149 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  Reduced NMD activity (lower NMD score) predicts improved CPI response across >1,000 patients, independent of TMB or tumor type

  tcga a375 reporter patient-derived multi-omics crispr-cas9 sirna